PPARγ and PPARGC1B polymorphisms modify the association between phthalate metabolites and breast cancer risk

Biomarkers

Volumn 18, Issue 6, 2013, Pages 493-501

  Martínez Nava, Gabriela A ^a   Burguete García, Ana I ^a   López Carrillo, Lizbeth ^a   Hernández Ramírez, Raúl U ^a   Madrid Marina, Vicente ^a   Cebrián, Mariano E ^b  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Breast cancer; gene environment interaction; phthalates; PPAR ; PPARGC1B

Indexed keywords

DRUG METABOLITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PHTHALIC ACID; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG URINE LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; POPULATION BASED CASE CONTROL STUDY; POPULATION DYNAMICS;

BREAST NEOPLASMS; CARRIER PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHTHALIC ACIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA;

EID: 84885223019     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.816776     Document Type: Article

References (42)

1. Barr DB, Wilder LC, Caudill SP, et al. (2005). Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect 113: 192-200.
2. Benjamini Y, Hochberg Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57:289-300.
3. Black MH, Fingerlin TE, Allayee H, et al. (2008). Evidence of interaction between PPARG2 and HNF4A contributing to variation in insulin sensitivity in Mexican Americans. Diabetes 57:1048-56.
4. Deeb SS, Fajas L, Nemoto M, et al. (1998). A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-7.
5. Desvergne B, Feige JN, Casals-Casas C. (2009). PPAR-mediated activity of phthalates: a link to the obesity epidemic? Mol Cell Endocrinol 304:43-8.
6. Duty SM, Singh NP, Silva MJ, et al. (2003). The relationship between environmental exposures to phthalates and DNA damage in human sperm using the neutral comet assay. Environ Health Perspect 111: 1164-9.
7. Elstner E, Muller C, Koshizuka K, et al. (1998). Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95:8806-11.
8. Fenner MH, Elstner E. (2005). Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs 14:557-68.
9. Hatch EE, Nelson JW, Qureshi MM, et al. (2008). Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999-2002. Environ Health 7:27. doi:10.1186/1476-069X-7-27.
10. Hauser R, Calafat AM. (2005). Phthalates and human health. Occup Environ Med 62:806-18.
11. Hauser R, Meeker JD, Singh NP, et al. (2007). DNA damage in human sperm is related to urinary levels of phthalate monoester and oxidative metabolites. Hum Reprod 22:688-95.
12. Hsieh TH, Tsai CF, Hsu CY, et al. (2012a). Phthalates stimulate the epithelial to mesenchymal transition through an HDAC6-dependent mechanism in human breast epithelial stem cells. Toxicol Sci 128:365-76.
13. Hsieh TH, Tsai CF, Hsu CY, et al. (2012b). Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway. FASEB J 26:778-87.
14. Huang PC, Kuo PL, Guo YL, et al. (2007). Associations between urinary phthalate monoesters and thyroid hormones in pregnant women. Hum Reprod 22:2715-22.
15. Hurst CH, Waxman DJ. (2003). Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci 74: 297-308.
16. International HAPMAP Project. (2010). HapMap Data Rel 28 Phase I+III. Available from: http://hapmap.ncbi.nlm.nih.gov/ [last accessed 20 August 2010].
17. Jeninga EH, Gurnell M, Kalkhoven E. (2009). Functional implications of genetic variation in human PPARgamma. Trends Endocrinol Metab 20: 380-7.
18. Jiang WG, Douglas-Jones A, Mansel RE. (2003). Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer 106:752-7.
19. Kato K, Silva MJ, Needham LL, Calafat AM. (2005). Determination of 16 phthalate metabolites in urine using automated sample preparation and on-line preconcentration/high-performance liquid chromatography/ tandem mass spectrometry. Anal Chem 77:2985-91.
20. Kaya T, Mohr SC, Waxman DJ, Vajda S. (2006). Computational screening of phthalate monoesters for binding to PPARgamma. Chem Res Toxicol 19:999-1009.
21. Kressler D, Schreiber SN, Knutti D, Kralli A. (2002). The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. J Biol Chem 277:13918-25.
22. Lewontin RC. (1964). The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 49:49-67.
23. Li Y, Wedren S, Li G, et al. (2011). Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer. Breast Cancer Res 13:R10. doi:10.1186/bcr2817.
24. Lopez-Carrillo L, Bravo-Alvarado J, Poblano-Verastegui O, Ortega Altamirano D. (1997). Reproductive determinants of breast cancer in Mexican women. Ann N Y Acad Sci 837:537-50.
25. Lopez-Carrillo L, Hernandez-Ramírez RU, Calafat AM, et al. (2010). Exposure to phthalates and breast cancer risk in northern Mexico. Environ Health Perspect 118:539-44.
26. Memisoglu A, Hankinson SE, Manson JE, et al. (2002). Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body mass. Pharmacogenetics 12:597-603.
27. Michalik L, Desvergne B, Wahli W. (2004). Peroxisome- proliferatoractivated receptors and cancers: complex stories. Nat Rev Cancer 4: 61-70.
28. Mueller E, Smith M, Sarraf P, et al. (2000). Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A 97:10990-5.
29. National Research Council. (2008). Phthalates and cumulative risk assessment: the task ahead. Washington, DC: National Academies Press.
30. Pignatelli M, Cocca C, Santos A, Perez-Castillo A. (2003). Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene 22: 5446-50.
31. Reddy BS, Rozati R, Reddy BV, Raman NV. (2006). Association of phthalate esters with endometriosis in Indian women. BJOG 113: 515-20.
32. Tapia-Conyer R, Gutierrez G, Sepulveda J. (1992). Methodology of the National Seroepidemiologic Survey, Mexico. Salud Publica Mex 34: 124-35.
33. Tontonoz P, Spiegelman BM. (2008). Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77:289-312.
34. Travis RC, Reeves GK, Green J, et al. (2010). Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet 375:2143-51.
35. Venkata NG, Robinson JA, Cabot PJ, et al. (2006). Mono(2- ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast. Toxicol Lett 163:224-34.
36. Vogel U, Christensen J, Nexo BA, et al. (2006). Peroxisome proliferatoractivated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28:427-34.
37. Wang Y, McCullough ML, Stevens VL, et al. (2007). Nested casecontrol study of energy regulation candidate gene single nucleotide polymorphisms and breast cancer. Anticancer Res 27:589-93.
38. Weuve J, Hauser R, Calafat AM, et al. (2010). Association of exposure to phthalates with endometriosis and uterine leiomyomata: findings from NHANES, 1999-2004. Environ Health Perspect 118:825-32.
39. Wirtenberger M, Tchatchou S, Hemminki K, et al. (2006). Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis 27:2201-8.
40. World Cancer Research Fund/American Institute for Cancer Research. (2007). Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC: AICR.
41. Wu MH, Chu CH, Chou YC, et al. (2011). Joint effect of peroxisome proliferator-activated receptor gamma genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a casecontrol study in Taiwan. Breast Cancer Res Treat 127:777-84.
42. Yee LD, Guo Y, Bradbury J, et al. (2003). The antiproliferative effects of PPARgamma ligands in normal human mammary epithelial cells. Breast Cancer Res Treat 78:179-92.